Harvard MedTech’s Vx Therapy Is Effective in Promoting Pain Resiliency

The combination of virtual reality and behavioral health is a novel and effective option for resolving pain in the workplace, according to results of an article published October 16, 2021, in the peer-reviewed journal “Pain and Therapy.”

“Up until now, the primary way to treat people with chronic pain or the effects of trauma was to use drugs, surgery, or long-term therapy,” said Gerry Stanley, M.D., one of the study authors and Chief Medical Officer for Harvard MedTech. “Now we understand that targeted therapy using virtual reality and customized coaching, all delivered within the home, can help the brain override the experience of pain, anxiety and depression, without the potential dangers of drugs or surgery. It is a revolutionary breakthrough in how we can treat these patients, alleviating their suffering and helping them to return to their normal lives.”

A deeper understanding of how the brain can re-train itself to heal from trauma plus a heavier reliance on remote therapy during the pandemic are behind the emerging interest in virtual reality, combined with behavioral health, to treat pain and trauma. The impact of the virtual reality experience is supported by the Gate Control Theory of pain, which posits that alternative stimuli can reduce the intensity of physical pain by blocking pain messages at nerve gates in the spinal cord.

The “Pain and Therapy” article documents results with a cohort of adult patients aged 18 – 65 who were treated from April 2019 to April 2020 for acute or chronic workplace injuries and were on workers compensation. All patients were referred to and overseen by a prescribing physician and referred to the Harvard MedTech Vx Pain Relief Program by orthopedic specialists, pain specialists, primary care physicians and occupational health providers.

Patients considerably reduced mean pain scores at each week, averaging a reduction of 40% while using the virtual reality headset. Their mean daily time spent thinking about pain symptoms decreased from 9.78 hours at the start of therapy to 2.76 hours after completing the 12-week program, representing a 72% reduction.

Reduction in reliance on opioids for pain control was also recorded with 69% of patients reporting a decrease in opioid use. Patients experienced a 115% increase in the duration of their sleep and a 280% increase in the subjective quality of their sleep. Finally, patients reported up to 750% improvement in the attainment of personal goals related to physical activities, social activities, attention and focus, and physical endurance.

As a result of these findings, the authors concluded that the program appears to provide meaningful reductions in pain and opioid use, while also improving the psychosocial aspects of pain, such as sleep, behavior, and physical activity.

In addition to Dr. Stanley, study authors include A. Abd-Elsayed, Department of Anesthesiology, School of Medicine and Public Health, University of Wisconsin, and N. Hussain, Department of Pain Medicine, Beth Israel, Deaconess Medical Center, Harvard Medical Center reports the company.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.
“These study results are highly encouraging especially given the short treatment duration of 10 days with BX004,” said Jonathan Solomon, Chief Executive Officer of BiomX. “In Part 2 of the study, BX004 showed clinically meaningful improvement in pulmonary function compared to placebo, as measured by relative FEV11 improvement (5.67% at Day 17, 1 week after end of treatment) and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain (8.87 points at Day 17) in a predefined subgroup of patients with reduced lung function.”  

By using this website you agree to accept Medical Device News Magazine Privacy Policy